CAD106, a vaccine co-developed by Novartis and Cytos that targets the amyloid β peptide, has shown early hints of immune responses in a clinical trial in people with Alzheimer's disease. This vaccine could have potential to slow the development of the disease.
Swiss researchers claim to have found a 'one size fits all' allergy shot for hay fever, asthma and eczema, adding that it could be available within four to five years, the Telegraph reports. The
Further bolstering its ambitious vaccine program, Pfizer has teamed up with Cytos Biotechnology to develop, manufacture and commercialize vaccines for a defined number of human diseases. Cytos gains
New data from a small human study of Cytos' blood pressure vaccine has stirred